Editor's Note: Green and red arrows refer to intraday stock price movement.NEW YORK ( TheStreet) -- CHANGE IN RATINGS Biogen Idec ( BIIB) upgraded at Credit Suisse from Neutral to Outperform. $126 price target. Estimates also boosted, given higher expectations for BG12. Boston Scientific ( BSX) rated new Buy at Stifel Nicolaus. $9 price target. Earnings growth could soon begin to accelerate. F5 Networks ( FFIV) upgraded at Barclays from Equal Weight to Overweight. $125 price target. Estimates also increased through 2012. F5's revenue pipeline and market are healthy. Forest Oil ( FST) upgraded at Stifel from Hold to Buy, Stifel Nicolaus said. $34 price target. Stock has pulled back to an attractive level. Hexcel ( HXL) upgraded at Keybanc from Hold to Buy. $28 price target. Company is leveraged to higher commercial aerospace demand. Polo Ralph Lauren ( RL) rated new Outperform at Wells. Recent investments should help future growth. Synovus Financial ( SNV) downgraded at Wunderlich from Buy to Hold. $2.50 price target. Company still faces significant earnings headwinds. Susquehanna ( SUSQ) upgraded at KBW from Market Perform to Outperform, Keefe, Bruyette & Woods said. Valuation call, based on a $10 price target. Western Refining ( WNR) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $24 price target. Company is leveraged to a wider Brent-WTI spread. VCA Antech ( WOOF) rated new Outperform at Barrington Research. $28 price target. Company generates significant free cash flow. End of report.